Related Experiment Videos
Biomarkers for dysplastic Barrett's: ready for prime time?
Eleanor M Gregson1, Rebecca C Fitzgerald
1MRC Cancer Unit, Hutchison/MRC Research Centre, University of Cambridge, Biomedical Campus, Box 197, Cambridge, CB2 0XZ, UK, emg59@mrc-cu.cam.ac.uk.
World Journal of Surgery
|May 22, 2014
Summary
Biomarker research for Barrett's esophagus shows promise for improving patient care by offering less invasive and more accurate diagnostic tools. While p53 immunostaining is ready for clinical use, further validation is needed for other biomarkers.
Area of Science:
- Gastroenterology
- Oncology
- Biomarker Discovery
Background:
- Current surveillance for Barrett's esophagus is costly, invasive, and prone to misdiagnosis.
- There is a critical need for improved diagnostic methods in clinical practice.
- Biomarker development offers a potential solution to enhance patient care and diagnostic accuracy.
Purpose of the Study:
- To review recent advancements in biomarker development for Barrett's esophagus.
- To assess the potential clinical application of these novel biomarkers.
- To identify challenges and future directions in biomarker research.
Main Methods:
- Comprehensive literature review of recent studies on biomarker development for Barrett's esophagus.
- Focus on studies aligning with Early Detection Research Network phases three and four.
- Analysis of various biomarker types including genetic mutations, methylation, gene expression, and glycosylation.
Main Results:
- Multiple candidate biomarkers and panels have been investigated, including gene mutations, methylation, gene expression, and glycosylation.
- Immunostaining for p53 is identified as a biomarker ready for clinical application, recommended as an adjunct to histology.
- Other biomarkers require further prospective validation before widespread clinical adoption.
Conclusions:
- Significant progress has been made in biomarker development for Barrett's esophagus.
- Further prospective validation studies are necessary for most biomarkers due to cohort size and cost limitations.
- Continued research is essential to realize the potential of biomarkers in improving patient care for Barrett's esophagus.